ADARx Pharmaceuticals closes IPO and AbbVie private placement
The San Diego biotech raised roughly $446.3 million in its Nasdaq offering alongside an $89.3 million concurrent stock purchase by AbbVie.
SEC filing
Latest
3 stories
Monday, September 28
Friday, September 25
ADARx prices IPO at $17 per share, AbbVie to buy stake
ADARx Pharmaceuticals sold 26.25 million shares in its Nasdaq debut and will use proceeds to fund late-stage siRNA programs including a Phase 3 hereditary angioedema trial.
SEC filing
Friday, September 4
ADARx Pharmaceuticals files S-1 for Nasdaq IPO under ticker ADRX
The San Diego siRNA drugmaker seeks to list its three clinical-stage and two preclinical programs, backed by a $335 million AbbVie upfront payment.
SEC filing